Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
62 results about "Gallbladder cancer" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Tumor that develops in the gallbladder, a small organ below the liver.
Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
InactiveUS20150132253A1Effectively preventingEffectively treatingHeavy metal active ingredientsOrganic active ingredientsDiseaseCombined Modality Therapy
The present invention provides a combination therapy for effectively treating and / or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
Owner:ASTELLAS PHARMA INC +1
Monoclonal antibodies against claudin-18 for treatment of cancer
The present invention provides antibodies useful as therapeutics for treating and / or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.
Owner:ASTELLAS PHARMA INC +1
ERBB signal pathway mutation targeted sequencing method for prognosis evaluation of gallbladder carcinoma
InactiveCN104032001AHelp to establishAids in diagnosisMicrobiological testing/measurementGenes mutationSignaling Pathway Gene
The invention relates to an ERBB signal pathway mutation targeted sequencing method for the prognosis evaluation of gallbladder carcinoma and provides an application of an ERBB signal pathway mutation targeted sequencing reagent / kit for gallbladder carcinoma patients. In the invention, the whole-genome exon technology is adopted for performing mutation target sequencing of the ERBB signal pathway of a gallbladder carcinoma patient; and in combination with the pathological clinical data of the gallbladder carcinoma patient, the Kaplan-Meier survival curve analysis indicates that the lifetime of the patient after operation is closely related to the gene mutation of the ERBB signal pathway, and the multiple-factor analysis of Cox risk regression model indicates that the gene mutation of the ERBB signal pathway can serve as an independent prognosis factor of gallbladder carcinoma. The prompt of screening the ERBB signal pathway related gene mutation of the gallbladder carcinoma cancer is favorable to the gene-level diagnosis and parting of gallbladder carcinoma, the establishment of therapeutic target, the prognosis analysis and the like.
Owner:XIN HUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Pharmaceutical composition for treatment and/or prevention of gallbladder cancer
ActiveUS9428581B2Treatment and prevention of gallbladder cancerReduce usageImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsBULK ACTIVE INGREDIENTActive ingredient
Provided is an antibody effective for treatment and / or prevention of gallbladder cancer. A pharmaceutical composition for treatment and / or prevention of gallbladder cancer contains as an active ingredient an antibody or a fragment thereof having immunological reactivity with a CAPRIN-1 protein or a fragment thereof comprising at least seven consecutive amino acid residues of the amino acid sequence of the protein.
Owner:TORAY IND INC
Methods and biomarkers for detection of gastrointestinal cancers
InactiveUS20140031257A1Nucleotide librariesMicrobiological testing/measurementGastrointestinal cancerBlood plasma
The present invention relates to methods and biomarkers (e.g., epigenetic biomarkers) for detection of gastrointestinal cancers (e.g., colorectal cancer, gastric cancer, pancreatic cancer, liver cancer, cancer of the gall bladder and / or bile ducts (e.g., cholangiocarcinoma)) in biological samples (e.g., tissue samples, stool samples, blood samples, plasma samples, cell samples, gall samples, bile samples, serum samples).
Owner:UNIV OSLO HF
Anti-cancer agent
The invention relates to an anti-cancer agent containing α-chain protein (α-fragment) of HGF (hepatocyte growth factor) as an active ingredient. The active ingredient of α-fragment has a specific suppressing effect on invasion and metastasis of cancer cells such as gallbladder cancer, lung cancer and other, which are highly metastatic and result in a high mortality. Therefore, the agent of the invention is used in treatment and prevention of cancer as an anti-cancer agent, and is extremely useful clinically.
Owner:NAKAMURA TOSHIKAZU
Model for evaluating HR defect and application
ActiveCN110570922AImprove anti-tumor efficacyAvoid situations where resistance existsDrug and medicationsMicrobiological testing/measurementCancer cellMedicine
The present invention discloses a model for evaluating an HR defect and its application. Based on a tumor individualized chemotherapy strategy, the method evaluates whether HR in gallbladder cancer cells is defective by using an existing HR-related indicator, and inhibits autophagy and PARP treatment according to normal HR or defective HR, improves the anti-tumor efficacy of a chemotherapy regimenFAM, and avoids the occurrence of resistance after multiple rounds of highly toxic medication for the patient. A multi-molecular marker used for detecting gallbladder cancer cells contains only 15 genes, is liable to clinical trials, reduces the cost of detection, and is not affected by the batch effect of experiments or the difference in the detection platforms, does not require data standardization between multiple samples before use, and is easy to use.
Owner:ZHEJIANG UNIV
Method for preparing human gallbladder cancer cell line resistant to oxaliplatin
ActiveCN108384757AThe method is simpleShort build timeCell culture active agentsTumor/cancer cellsDrug resistanceBiology
The invention provides a method for preparing a human gallbladder cancer cell line resistant to oxaliplatin. The method comprises the following steps that human gallbladder cancer cells in the exponential phase are inoculated in a DMEM culture solution containing newborn fetal calf serum for culturing, oxaliplatin is added into the culture solution for inducing, wherein after the cells recover thenormal growth, the concentration increases progressively, when the cells can normally grow and perform passage at the concentration of 0.5 [mu] mol / L, oxaliplatin is adopted for carrying out impact culture, a culture medium with the concentration of oxaliplatin being 0.5 [mu] mol / L is used for culturing, after the cells grow and perform passage stably, impact is carried out again, then the concentration increases progressively, oxaliplatin is used for carrying out impact inducing till the cells can grow in oxaliplatin of 10.0 [mu] mol / L, and finally, the human gallbladder cancer cell line resistant to oxaliplatin which can stably grow and perform passage in the culture system containing 10.0 [mu] mol / L of oxaliplatin is obtained. The method for establishing the human gallbladder cancer cell line resistant to oxaliplatin is simple, convenient and feasible, the establishing time is short, and the drug resistance index is close to 20.
Owner:ZHONGSHAN HOSPITAL FUDAN UNIV +1
Method for establishing prediction model for survival benefit of gallbladder cancer patient after chemoradiotherapy
PendingCN113571189AThe result is objective and accurateEasy to operateHealth-index calculationPatient-specific dataNomogram ChartClinico pathological
The invention relates to a method for establishing a prediction model for survival benefit of a gallbladder cancer patient after chemoradiotherapy. The method comprises the steps of acquiring clinical and pathological data of the gallbladder cancer patient; dividing the acquired data into a plurality of groups of data according to the TNM stages, and respectively judging whether the patient in each stage is benefited from adjuvant therapy or not; dividing the data corresponding to the TNM stages into a modeling group and an internal verification group; analyzing the prediction capability of clinical and pathological variables of the modeling group data on the total survival time OS through a single-factor COX risk scale model, and screening risk factors which significantly influence the total survival time OS of the patient in the modeling group; incorporating the screened risk factors into a multi-factor COX risk scale model for analysis, and screening out influence variables significantly influencing the total survival time OS of the patient; according to the obtained influence variables, drawing a column graph used for predicting the total survival time OS, and obtaining a prediction model; and verifying the model. Compared with the prior art, the method has the advantages of providing credible prediction and analysis results for the GBC patient, being simple and convenient to operate and the like.
Owner:ZHONGSHAN HOSPITAL FUDAN UNIV
Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
ActiveUS9433675B2High affinityStrong specificityHeavy metal active ingredientsBiocideDiseaseEsophageal cancer
The present invention provides a combination therapy for effectively treating and / or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
Owner:TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG UNIV MAINZ GEMEINNUETZIGE GMBH +1
Monoclonal antibody against claudin-18 for the treatment of cancer
The present invention provides antibodies, which can be used as a therapeutic agent for treating and / or preventing diseases associated with cells expressing CLD18, including tumor-related diseases, such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, Liver, head and neck, and gallbladder cancers.
Owner:ASTELLAS PHARMA INC +1
Pharmaceutical composition for treatment and/or prevention of gallbladder cancer
ActiveUS20150299314A1Treatment and prevention of gallbladder cancerReduce usageImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsBULK ACTIVE INGREDIENTActive ingredient
Provided is an antibody effective for treatment and / or prevention of gallbladder cancer. A pharmaceutical composition for treatment and / or prevention of gallbladder cancer contains as an active ingredient an antibody or a fragment thereof having immunological reactivity with a CAPRIN-1 protein or a fragment thereof comprising at least seven consecutive amino acid residues of the amino acid sequence of the protein.
Owner:TORAY IND INC
Method for inhibiting tumor growth by DDX24 helicase point mutation and application of DDX24 helicase
ActiveCN111254130AHydrolasesMicrobiological testing/measurementSquamous CarcinomasNasopharyngeal cancer
The invention discloses a newly discovered cancer promoting effect of DDX24 helicase, a method for realizing a cancer inhibition effect through point mutation and application of the DDX24 helicase. The contents of the invention comprise: 1, high expression of wild type DDX24 has significant correlation with tumor growth, and the growth of tumors can be promoted through high expression of the wildtype DDX24; 2, different from the mechanism of the pathogenic gene DDX24 for familial vascular malformation, DDX24 point mutation including K11E or E271K obviously inhibits the growth of tumors; 3, based on the new function and induced point mutation of DDX24 provided in the invention, a novel targeted therapy method can be provided for treatment of latent and refractory tumors, and a new thoughtcan also be provided for preparation of tumor-related vaccines; and 4, application of 1-3 described above is provided. The point mutation can be used for treating solid tumors including, but not limited to, squamous cell carcinoma of the head and the neck, esophageal cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, skin melanoma, lymphoma, adenoma, thoracic adenoma, lung cancer, colorectal cancer, gallbladder cancer, kidney cancer, bladder cancer, prostate cancer, breast cancer, ovarian cancer, endometrial cancer, cervical cancer, nasopharyngeal cancer, bone cancer andmalignant myoma.
Owner:THE FIFTH AFFILIATED HOSPITAL SUN YAT SEN UNIV
Application of ulinastatin in preparation of drug for treating gallbladder carcinomas
InactiveCN106110312AOpen up the application directionSignificant effectPeptide/protein ingredientsAntineoplastic agentsSide effectNude mouse
The invention belongs to the technical field of medicines, and particularly discloses application of ulinastatin in preparation of a drug for treating gallbladder carcinomas. It is proved through animal experiments that ulinastatin has an obvious inhibiting effect on human gallbladder carcinoma transplanted tumor in nude mice, is low in toxic and side effects and high in safety and can serve as a drug for treating the gallbladder carcinomas for use.
Owner:GUANGDONG TECHPOOL BIO-PHARMA CO LTD
Liver and gallbladder cancer cell postoperative monitor based on overall association medical logic and use method of liver and gallbladder cancer cell postoperative monitor
InactiveCN112932448AFast diagnosisEasy diagnosisDiagnostic recording/measuringSensorsCancer cellEarmuffs
The invention discloses a liver and bile cancer cell postoperative monitor based on overall association medical logic, which comprises a special earphone worn on the two ears of a patient, and the special earphone comprises a transmitter and a receiver; the special earphone is electrically connected with a noise voltage generator, and the noise voltage generator is connected with a processor through a differential amplifier; the processor is connected with the pulse width modulation circuit; the invention further discloses a use method of the liver and bile cancer cell postoperative monitor based on the overall association medical logic, and the use method comprises the steps that S1, a detected person wears the specially-made earmuff, electromagnetic waves are emitted through the left earmuff and reach the cerebral cortex, and an external magnetic field is generated through electromagnetic resonance; the method is simple, the neurons can be stimulated to generate chemical electric signals, the chemical electric signals are transmitted to tissue cells of organs of the whole body through the neurons to cause resonance, and the disease state and degree of the human cell level are judged after analysis so as to count significance and predict clinical feature significance.
Owner:芭雅医院投资管理(上海)有限公司
Big data-based liver and bile cancer cell postoperative monitor and use method thereof
InactiveCN112885477AConvenient treatmentImplement storageMedical simulationDiagnostic signal processingDiseaseCancer cell
The invention discloses a liver and bile cancer cell postoperative monitor based on big data, which comprises a detection device being a special earphone, wherein the detection device is electrically connected with a data transmission device, the data transmission device is electrically connected with a processor, and the processor is connected with a medical system and a cloud server; thus, the early warning is carried out on diseases through the medical system and the cloud server. The invention further discloses a using method of the liver and bile cancer cell postoperative monitor based on the big data, which comprises the following steps: S1, searching information of a to-be-detected person through the to-be-detected person, and then preparing related information of the to-be-detected person for research. The postoperative monitor is reasonable in structure, neurons can be stimulated to generate chemical electric signals, and the disease state and degree of the human cell level are judged after analysis, so that postoperative treatment of liver and gallbladder cancer cells is facilitated.
Owner:芭雅医院投资管理(上海)有限公司
Honey health preserving wine
InactiveCN107937203AImprove performanceGood effectNervous disorderAnthropod material medical ingredientsHigh concentrationAdditive ingredient
The invention discloses a honey health preserving wine, which comprises the following raw materials and auxiliary materials: 3 g of honeybee pupae, 3 g of bee, 3 g of honey, 10 g of red date, 10 g ofChinese wolfberry, 5 g of millettia speciosa champ, 500 g of Baijiu with an alcoholicity of 62 DEG, and 10 g of longan. According to the present invention, leaching, extraction of the medicinal components of honey and bee venom and prepared fermentation with high-concentration Baijiu are performed, and finally the high-alcohol-concentration honey health preserving wine is obtained through the secondary fermentation; the honey health preserving wine has advantages of stable performance, good efficacy, golden color, unique fragrance and delicious taste, has effects of wind dampness removing, wind cold removing, blood pressure lowering, paralysis treating, impotence treating, prospermia treating, blood fat lowering, face nourishing, blood enriching and qi supplementing, contains the medicinalcomponents of bee venom, can be used for treating chronic bronchitis, can further be used for the assisted treatment of acquired immunodeficiency syndrome, lung cancer, gallbladder cancer and other cancers, can be used for coated treatment of psoriasis and eczema, and has significant treatment effects.
Owner:海南鑫元利酒业有限公司
Monoclonal antibody against claudin-18 for the treatment of cancer
Owner:ASTELLAS PHARMA INC +1
Traditional Chinese medicine composition for use after gallbladder cancer surgery and preparation method thereof
InactiveCN106880753ARapid hemostasisPromote healingDispersion deliveryDigestive systemBletilla striataWater Chestnuts
Owner:江志杰
Application of ulinastatin-containing pharmaceutical composition to preparation of medicine for treating carcinoma of gall-bladder
ActiveCN105999245AOpen up the application directionSignificant effectPowder deliveryOrganic active ingredientsSide effectNude mouse
The invention belongs to the field of medical technology and particularly discloses application of an ulinastatin-containing pharmaceutical composition to preparation of a medicine for treating carcinoma of the gall-bladder. The pharmaceutical composition comprises ulinastatin and beta-aescin natrum. Animal tests verify that the pharmaceutical composition can play an obvious inhibition function on human gall-bladder carcinoma nude-mouse transplanted tumor, is low in toxic and side effect and high in security and can serve as the medicine for treating carcinoma of the gall-bladder.
Owner:GUANGDONG TECHPOOL BIO-PHARMA CO LTD
Kit for early diagnosis of gallbladder cancer and application thereof
The invention relates to a kit for early diagnosis of gallbladder cancer and application thereof. The kit comprises a CTNNB1 mutation detection reagent and an ARID2 mutation detection reagent. According to the invention, senescence is determined to be a main factor for promoting accumulated mutations and CTNNB1 and ARID2 mutations in the tumors, especially CTNNB1 mutation plays a key role. According to the invention, a foundation is laid for early diagnosis and effective treatment of gallbladder cancer through the understanding of reconstruction of gallbladder cancer transformation and canceration evolution trajectory.
Owner:普瑞基准科技(北京)有限公司 +1
Gallbladder cancer diagnostic and prognostic marker pim1
The invention discloses gallbladder cancer diagnosis and prognosis judgment marker PIM1, and also discloses a gallbladder cancer diagnosis and prognosis judgment kit, which can be used for diagnosis, prediction, detection or screening of human gallbladder cancer cell proliferation, gallbladder cancer clinical stage or gallbladder cancer cancer patient prognosis. The invention also discloses the use of the PIM1 protein inhibitor in the preparation of anti-gallbladder cancer drugs. The present invention shows that PIM1 has very important significance in clinical practice, and may become a new generation of tumor biodiagnostic markers and molecular targets for tumor treatment, and opens up the research of new targets for gallbladder cancer mainly based on PIM1. Open up a new way for the development of new anti-tumor drugs.
Owner:THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV
Method for specific sorting and identification detection of CTC in serum of biliary tract tumors
PendingCN111518767AImprove sorting efficiencyStrong specificityCell dissociation methodsMicrobiological testing/measurementWhite blood cellBiliary tract
The present invention provides a method for specific sorting of CTC in serum of biliary tract tumors. An appropriate amount of peripheral blood from patients with biliary tract tumors is taken and placed in anticoagulation centrifuge tubes and whole blood samples are mixed evenly; the collected blood samples are sequentially subjected to sample processing of plasma protein and plasma nucleic acidremoval, red blood cell removal, layered centrifugation and white blood cell removal; an HSPG antibody or a SDC1 subtype antibody or a SDC2 subtype antibody or a GPC1 subtype antibody or a GPC3 subtype antibody is used to combine with immunomagnetic beads to capture HSPG positive or SDC1 positive or SDC2 positive or GPC1 positive or GPC3 positive CTC. HSPG is used as a relatively specific functional tumor molecular marker for CTC sorting of gallbladder cancer and cholangiocarcinoma, thereby improving sorting efficiency of biliary tract tumor CTC, a set of HSPG-based CTC molecular typing scoring system is established, the high-specificity and high-sensitivity detection method for the biliary tract tumors is otbained, and based on the high-efficiency sorting of the biliary tract tumor CTC, downstream RNA-seq and gene NGS detection is conducted to obtain tumor-specific molecular information to improve specificity.
Owner:易滨 +1
Traditional Chinese medicine combination for treating hepatobiliary diseases and preparation method thereof
InactiveCN107397776AHas an immunomodulatory effectRegulate hormonesOrganic active ingredientsDigestive systemHepatobiliary diseaseGanoderma lucidum
The invention discloses a traditional Chinese medicine combination for treating hepatobiliary diseases and a preparation method thereof. The traditional Chinese medicine combination is composed of the following raw materials, by weight, of 200-300 parts of ganoderma lucidum soak solutions, 30-60 parts of antrodia camphorata polysaccharide, 70-100 parts of selenium-enriched pleurotus ostreatus fruiting body powder, 10-20 parts of bear bile powder, 100-200 parts of panax notoginseng powder, 80-120 parts of rock candies and 180-220 parts of tilia honey. The traditional Chinese medicine combination has good curative effect on treating liver cirrhosis, viral hepatitis type B, cholangitis, gallstones, a bile duct cancer and a gallbladder cancer.
Owner:林树芳
Compound containing imatinib and plant polysaccharide
InactiveCN109010354AImprove anti-tumor effectOrganic active ingredientsAntineoplastic agentsKidney cancerImatinib
The invention provides a compound containing imatinib or pharmaceutically acceptable salt of the imatinib and plant polysaccharide. The plant polysaccharide is selected from one of ganoderma lucidum polysaccharide, coriolus versicolor polysaccharide and cynanchum otophyllum polysaccharide. Animal tests show that the compound can generate a synergistic anti-tumor effect on liver cancer, gastric cancer, a lung carcinoma model, gallbladder carcinoma and / or kidney cancer.
Owner:黄泳华
Method of treating carcinoma
A method of treating patients suffering from carcinoma of intrahepatic or extra hepatic bile duct or gall bladder which is locally advanced or metastatic, by intravenously administering to the patient, paclitaxel in the form of a nanodispersion. The nanodispersion comprises particles with a mean particle size less than 300 nm and is free of polyoxyethylated castor oil and free of a protein.
Owner:SUN PHARMA INDS
A long usnea derivative and its use in the preparation of drugs for the treatment of gallbladder cancer
ActiveCN111393278BEnhanced inhibitory effectLittle side effectsOrganic active ingredientsHeavy metal active ingredientsCancer cellSide effect
The invention provides an usnea longifolia derivative and application thereof in preparation of a medicine for treating gallbladder cancer. The usnea longifolia derivative has a chemical name of 3, 6-diacetyl-2, 7, 9-trihydroxy-8, 9b-dimethyl-1 (9bH)-dibenzofuranone, has an effect of inhibiting activity of human gallbladder cancer cells and has a small toxic effect on normal cells. The compound can be independently used in the treatment of gallbladder cancer and can also be used in combination with other drugs. The inventor of the invention unexpectedly finds that the compound can achieve a better effect of inhibiting cholecystoma cancer cells when being combined with cisplatin and can effectively slow down the side effects generated by cisplatin. The medicine for treating the gallbladdercancer has great application potential.
Owner:山西白求恩医院
Novel peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
ActiveUS20180327474A1Increased riskIncrease the importanceAntibody mimetics/scaffoldsTransferasesAdditive ingredientEx vivo
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Owner:IMMATICS BIOTECHNOLOGIES GMBH
Application of compound as CYP2E1 inhibitor
PendingCN114099503AAntibacterial agentsOrganic active ingredientsHepatic inflammationHepatic fibrosis
The invention discloses an application of a compound as a CYP2E1 inhibitor, which is characterized in that the compound or a salt thereof as an inhibitor takes CYP2E1 as a target spot and is combined with the CYP2E1, and the CYP2E1 inhibitor has an inhibition effect on CYP2E1. The inhibitor can be used for preventing and treating tumors such as liver cancer, glioma, ovarian cancer, bladder cancer and gallbladder cancer. Similarly, the inhibitor can also be used for preventing and treating other inflammation-related diseases such as liver injury, fatty liver, hepatitis, hepatic fibrosis, rheumatic and rheumatoid arthritis, sepsis, Alzheimer's disease, ischemic cerebral apoplexy, Parkinson's disease, hyperlipidemia, atherosclerosis, coronary heart disease, diabetes mellitus and the like.
Owner:上海灵希生物科技发展有限公司
Application of zedoary cyclic diolefine in preparation of medicine for resisting neoplasm metastasis
InactiveCN102100688AInhibit tumor metastasisEnhanced inhibitory effectOrganic active ingredientsAntineoplastic agentsLymphatic SpreadProstate cancer
The invention belongs to the field of pharmacy, and provides application of zedoary cyclic diolefine in preparation of a medicine for resisting neoplasm metastasis, and in particular relates to application in the preparation of medicines for resisting neoplasm metastasis, such as liver cancer, gastric cancer, carcinoma of urinary bladder, breast cancer, colon cancer, kidney cancer, esophagus cancer, gallbladder cancer, ovarian cancer, pancreatic cancer, carcinoma of uterine cervix, thyroid cancer, prostatic cancer, oral cancer, lung cancer and the like. The zedoary cyclic diolefine plays a role in resisting the neoplasm metastasis through inhibiting the expression of proteins related to neoplasm cell metastasis.
Owner:HANGZHOU MINSHENG PHARM CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com